BMS-986517

DRUG2 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Bristol-Myers Squibb

Conditions

Advanced Solid TumorsSolid Tumours

Phase 1

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

RecruitingNCT07160725

Bristol-Myers SquibbSolid Tumours

Start: 2025-10-15End: 2028-08-01Target: 540Updated: 2026-08-11

A Phase 1/2a, First-in-human, Open label Study of BMS-986517 as Monotherapy in Adult Participants with Advanced Solid Tumors

RecruitingCTIS2025-522203-23-00

Bristol-Myers Squibb Services Unlimited CompanyAdvanced Solid Tumors

Start: 2025-12-18Target: 11Updated: 2025-11-07